DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Official Title

A Phase 2, Multicentre, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1


Some HER-2 breast cancer patients do not respond or build resistance to current treatment. DS-8201a is a new experimental product that is a combination of an antibody and a drug. It has not yet been approved for use. DS-8201a may slow down tumour growth. This might improve outcomes for these patients.

Trial Description

Primary Outcome:

  • Objective response rate (ORR) per imaging assessment
Secondary Outcome:
  • Duration of response
  • Best percent change in the sum of the longest diameters (SLD) of measurable tumours
  • Disease control rate (DCR)
  • Clinical benefit rate (CBR)
  • Progression-free survival
  • Overall survival (OS)
  • ORR assessed by the investigator based on RECIST version 1.1
  • Maximum plasma/serum concentration (Cmax)
  • Time to Cmax (Tmax)
  • Area under the concentration-time curve (AUC) from dosing until the last quantifiable concentration (AUClast)
  • AUC from the time of dosing until day 21 (AUC0-21d)

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society